Ibio, Inc.
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is not left to chance but guided by artificial intelligence to make therapeutic development smarter, more precise, and ultimately faster. With our RubrYc Discovery Platform we are pursuing hard-to-drug targets with greater potential and less competition. We have nine immuno-oncology candidates in our pipeline, including those for the potential treatment of solid tumors, glioblastoma, and head and neck cancers.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Plus, our?novel Glycaneering Development Services? provide greater control over the glycosylation of complex biopharmaceuticals. Glycaneering can deliver molecules with greater Antibody-Dependent Cellular Cytotoxicity [ADCC], facilitating the creation of more potent anti-cancer therapeutics. We’ve demonstrated the quality and potency of Glycaneered molecules for our clients, not to mention strong data we’ve generated on plant-made rituximab. We’ve also used Glycaneering to afucosylate our novel anti-CD25 mAb as we convert it from CHO cell production to FastPharming.
We have two facilities; our San Diego, CA, site houses early-stage drug discovery and process development, and our Bryan/College Station, TX, facilty supports bioanalysis, protein characterization, and bioprocess services.
Our experienced team of scientists and engineers helps our clients leverage all of FastPharming’s advantages over mammalian cell culture. We’re experts in plant-based recombinant protein expression and purification process development and are happy to help drug developers avoid expensive media development, risks associated with animal-origin raw materials, master cell bank creation, and other issues associated with mammalian cell culture processes.
iBio’s patented antibody discovery technology employs an artificial intelligence (AI) engine designed to actively guide the discovery process directly to a desired result. Our RubrYc Discovery Platform is comprised of three main components:
- An AI-driven Epitope Engineering Engine, which enables the active steering of antibody discovery to desirable binding sites on the target protein
- A modern Antibody Library of fully human sequences and a clinically validated framework
- An Antibody Optimizer for generating functionally enriched libraries from a template antibody
By moving beyond traditional “trial-and-error” methods, we believe our platform will enable us to bring cancer therapeutics based on previously undruggable proteins into the clinic faster and more cost-effectively – both for our own development and in partnership with others.